These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 12902992)

  • 21. Chronic buprenorphine reduces the response to sucrose-associated cues in non food-deprived rats.
    Hood S; Sorge RE; Stewart J
    Pharmacol Biochem Behav; 2007 Mar; 86(3):566-75. PubMed ID: 17346785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimentally induced aggressiveness in heroin-dependent patients treated with buprenorphine: comparison of patients receiving methadone and healthy subjects.
    Gerra G; Zaimovic A; Raggi MA; Moi G; Branchi B; Moroni M; Brambilla F
    Psychiatry Res; 2007 Jan; 149(1-3):201-13. PubMed ID: 17129610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
    Burke NN; Ferdousi M; Deaver DR; Finn DP; Roche M; Kelly JP
    Neuropharmacology; 2019 Mar; 146():327-336. PubMed ID: 30553825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.
    Jassar H; Nascimento TD; Kaciroti N; DosSantos MF; Danciu T; Koeppe RA; Smith YR; Bigal ME; Porreca F; Casey KL; Zubieta JK; DaSilva AF
    Neuroimage Clin; 2019; 23():101905. PubMed ID: 31279240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine.
    Upadhyay J; Anderson J; Baumgartner R; Coimbra A; Schwarz AJ; Pendse G; Wallin D; Nutile L; Bishop J; George E; Elman I; Sunkaraneni S; Maier G; Iyengar S; Evelhoch JL; Bleakman D; Hargreaves R; Becerra L; Borsook D
    Neuroimage; 2012 Feb; 59(4):3762-73. PubMed ID: 22119647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.
    Gerra G; Borella F; Zaimovic A; Moi G; Bussandri M; Bubici C; Bertacca S
    Drug Alcohol Depend; 2004 Jul; 75(1):37-45. PubMed ID: 15225887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic opioid antagonist treatment dose-dependently regulates mu-opioid receptors and trafficking proteins in vivo.
    Rajashekara V; Patel CN; Patel K; Purohit V; Yoburn BC
    Pharmacol Biochem Behav; 2003 Jul; 75(4):909-13. PubMed ID: 12957235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.
    Greenwald MK; Lundahl LH; Steinmiller CL
    Psychopharmacology (Berl); 2013 Feb; 225(4):811-24. PubMed ID: 23161001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.
    Jones JD; Madera G; Comer SD
    Pharmacol Biochem Behav; 2014 Jul; 122():299-306. PubMed ID: 24793093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings.
    Kosten TR; Morgan C; Kreek MJ
    Biol Psychiatry; 1992 Sep; 32(6):523-8. PubMed ID: 1445968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.
    Greenwald MK; Lundahl LH; Steinmiller CL
    Neuropsychopharmacology; 2010 Dec; 35(13):2624-37. PubMed ID: 20881947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between gene variants and response to buprenorphine maintenance treatment.
    Gerra G; Somaini L; Leonardi C; Cortese E; Maremmani I; Manfredini M; Donnini C
    Psychiatry Res; 2014 Jan; 215(1):202-7. PubMed ID: 24274990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats.
    Van Bockstaele EJ; Rudoy C; Mannelli P; Oropeza V; Qian Y
    J Neurosci Res; 2006 Feb; 83(3):508-14. PubMed ID: 16385558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
    Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
    Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study.
    Greenwald MK; Schuh KJ; Stine SM
    Am J Addict; 2003; 12(4):365-74. PubMed ID: 14504028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.
    Comer SD; Walker EA; Collins ED
    Psychopharmacology (Berl); 2005 Oct; 181(4):664-75. PubMed ID: 16025322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.